BRPI0813527A2 - Expressão diferencial de micro-rnas em corações humanos que não falham versus que falham - Google Patents

Expressão diferencial de micro-rnas em corações humanos que não falham versus que falham

Info

Publication number
BRPI0813527A2
BRPI0813527A2 BRPI0813527-4A2A BRPI0813527A BRPI0813527A2 BR PI0813527 A2 BRPI0813527 A2 BR PI0813527A2 BR PI0813527 A BRPI0813527 A BR PI0813527A BR PI0813527 A2 BRPI0813527 A2 BR PI0813527A2
Authority
BR
Brazil
Prior art keywords
fail
micro
versus
differential expression
human hearts
Prior art date
Application number
BRPI0813527-4A2A
Other languages
English (en)
Inventor
Jonathan David Port
Carmen Sucharov
Michael R Bristow
Original Assignee
Univ Colorado
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Colorado filed Critical Univ Colorado
Publication of BRPI0813527A2 publication Critical patent/BRPI0813527A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0813527-4A2A 2007-07-18 2008-07-18 Expressão diferencial de micro-rnas em corações humanos que não falham versus que falham BRPI0813527A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95056507P 2007-07-18 2007-07-18
PCT/US2008/070508 WO2009012468A2 (en) 2007-07-18 2008-07-18 Differential expression of micrornas in nonfailing versus failing human hearts

Publications (1)

Publication Number Publication Date
BRPI0813527A2 true BRPI0813527A2 (pt) 2014-12-30

Family

ID=40260401

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813527-4A2A BRPI0813527A2 (pt) 2007-07-18 2008-07-18 Expressão diferencial de micro-rnas em corações humanos que não falham versus que falham

Country Status (9)

Country Link
US (2) US20100267804A1 (pt)
EP (1) EP2179060B1 (pt)
JP (1) JP2010533503A (pt)
KR (1) KR20100049079A (pt)
CN (1) CN101802227B (pt)
AU (1) AU2008275877B2 (pt)
BR (1) BRPI0813527A2 (pt)
CA (1) CA2693031A1 (pt)
WO (1) WO2009012468A2 (pt)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2021495A4 (en) * 2006-05-09 2009-06-24 Musc Found For Res Dev Detecting diastolic heart failure by protease and protease inhibitor plasma profiling
US8445222B2 (en) * 2006-07-11 2013-05-21 Musc Foundation For Research Development Predicting heart failure following myocardial infarction by protease and protease inhibitor profiling
WO2008085895A2 (en) * 2007-01-04 2008-07-17 Musc Foundation For Research Development Predicting atrial fibrillation recurrence by protease and protease inhibitor profiling
DE102007052114B4 (de) 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
WO2009114681A2 (en) * 2008-03-13 2009-09-17 Dharmacon, Inc. Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy
WO2010126355A1 (en) * 2009-04-29 2010-11-04 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure
WO2010126370A2 (en) * 2009-04-29 2010-11-04 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure
WO2010129672A1 (en) 2009-05-05 2010-11-11 Miragen Therapeutics Lipophilic polynucleotide conjugates
WO2010129919A1 (en) * 2009-05-08 2010-11-11 Research Development Foundation Mirna expression in allergic disease
WO2010130351A1 (en) * 2009-05-15 2010-11-18 Bayer Schering Pharma Ag Micrornas as biomarkers and therapeutic targets for heart failure
US9512481B2 (en) * 2009-09-11 2016-12-06 The Regents Of The University Of Colorado, A Body Corporate Polymorphisms in the PDE3A gene
EP2496714B1 (en) 2009-11-04 2016-08-31 DiamiR, LLC Methods of using micro-rna from bodily fluids for diagnosis and monitoring of mild cognitive impairment
US8592151B2 (en) * 2009-11-17 2013-11-26 Musc Foundation For Research Development Assessing left ventricular remodeling via temporal detection and measurement of microRNA in body fluids
EP2327783A1 (en) * 2009-11-27 2011-06-01 Universitätsklinikum Freiburg Pharmaceutical composition comprising miRNA-100 and its use in the modulation of blood vessel growth
CA2783536A1 (en) * 2009-12-09 2011-06-16 Aviir, Inc. Biomarker assay for diagnosis and classification of cardiovascular disease
US20130005658A1 (en) * 2009-12-15 2013-01-03 Board Of Regents, The University Of Texas System Micro-rna regulation in ischemia and ischemia-reperfusion injury
GB201101400D0 (en) * 2011-01-26 2011-03-09 King S College London Detection method
WO2011154553A2 (en) * 2010-06-11 2011-12-15 Cellartis Ab Novel micrornas for the detection and isolaton of human embryonic stem cell-derived cardiac cell types
GB201012272D0 (en) * 2010-07-21 2010-09-08 Univ Coventry Assays for screening drug safety
AU2011323085B2 (en) * 2010-11-05 2014-10-30 Miragen Therapeutics Base modified oligonucleotides
CN102115787B (zh) * 2010-11-22 2012-12-19 中国科学院动物研究所 一种微小rna及其反义核酸在制备诊断、预防、治疗和/或预后评估心脏疾病的试剂盒或药物中的用途
CA2818174A1 (en) * 2010-12-15 2012-06-21 Miragen Therapeutics Blood-borne mirnas as surrogate markers of drug efficacy for cardiac conditions
WO2012094366A1 (en) * 2011-01-06 2012-07-12 Cardiodx, Inc. Circulating mirnas as biomarkers for coronary artery disease
CN102199625B (zh) * 2011-04-02 2012-09-19 中国人民解放军军事医学科学院生物工程研究所 一种miRNA转基因小鼠模型的构建方法
EP2699666B1 (en) 2011-04-18 2016-10-05 DiamiR, LLC miRNA-BASED UNIVERSAL SCREENING TEST (UST)
EP2718463B1 (en) * 2011-06-08 2016-01-20 Comprehensive Biomarker Center GmbH Complex sets of mirnas as non-invasive biomarkers for dilated cardiomyopathy
CN102266570A (zh) * 2011-07-08 2011-12-07 中国科学院动物研究所 miRNA-484的新用途及含有miRNA-484的药物组合物及其用途
CN102251037A (zh) * 2011-07-08 2011-11-23 中国科学院动物研究所 miRNA-23a反义核苷酸在制备用于治疗心脏病药物中的用途
KR20130026950A (ko) * 2011-09-06 2013-03-14 서울대학교산학협력단 ｍｉｃｒｏＲＮＡ４８６ 발현 억제제를 유효성분으로 포함하는 신경계 질환 예방 및 치료용 약학적 조성물
AU2012323924A1 (en) * 2011-10-14 2014-05-29 The Ohio State University Methods and materials related to ovarian cancer
ITRM20110685A1 (it) 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
WO2013103687A2 (en) * 2012-01-03 2013-07-11 Rhode Island Hospital Treatment of heart failure and sudden cardiac death
DE102012101557A1 (de) * 2012-02-27 2013-08-29 Charité Universitätsmedizin Berlin Verwendung von microRNAs oder Genen als Marker zur Identifizierung, Diagnose und Therapie einzelner nicht-ischämischer Kardiomyopathien oder Speichererkrankungen des Herzens
WO2013155085A1 (en) * 2012-04-09 2013-10-17 Creighton University Methods and biomarkers for osteoporosis
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
CN102886050B (zh) * 2012-07-16 2014-04-02 中国科学院动物研究所 miRNA-489的用途及药物组合物
CN102888403A (zh) * 2012-07-19 2013-01-23 中国科学院动物研究所 miRNA-539及其反义核苷酸的用途和其药物组合物
US9493838B2 (en) * 2012-10-10 2016-11-15 Beth Israel Deaconess Medical Center, Inc. Biomarkers and treatments for heart failure
US9220721B2 (en) 2012-10-11 2015-12-29 Salk Institute For Biological Studies Methods for heart regeneration
WO2014071200A1 (en) * 2012-11-02 2014-05-08 The Regents Of The University Of Colorado, A Body Corporate Beta blocker responder status assays and related materials and methods
CA2893639C (en) * 2012-12-04 2021-01-05 F. Hoffmann-La Roche Ag Biomarkers in the selection of therapy of heart failure
EP2757157A1 (en) * 2013-01-17 2014-07-23 Ecole Polytechnique Federale de Lausanne (EPFL) Modulation of mitophagy and use thereof
CN103290012B (zh) * 2013-05-16 2015-09-16 南京市妇幼保健院 与胎儿先天性心脏病相关的母体血清/血浆miRNA标志物mir-22及其应用
US11098362B2 (en) 2013-11-18 2021-08-24 Diamir, Llc Methods of using miRNAs from bodily fluids for detection and monitoring of Parkinson's disease (PD)
CN104140968B (zh) * 2014-06-23 2017-01-04 杭州师范大学 一种放射治疗靶向增敏剂及其应用
CN104225598A (zh) * 2014-09-29 2014-12-24 武汉大学 microRNA150在治疗动脉粥样硬化中的功能和应用
EP3034623A1 (en) * 2014-12-18 2016-06-22 Centro de Investigación Biomédica en Red (CIBER) Method for predicting response to continuous positive air pressure treatment
AU2016209386A1 (en) 2015-01-20 2017-08-03 MiRagen Therapeutics, Inc. miR-92 inhibitors and uses thereof
CN107207557B (zh) * 2015-01-26 2020-07-10 中国科学院动物研究所 miRNA对m6A修饰水平的调控方法及其应用
ES2754384T3 (es) * 2015-02-17 2020-04-17 Nestle Sa Métodos para diagnosticar la enfermedad valvular crónica
EP3294910B1 (en) * 2015-05-08 2021-03-17 Agency For Science, Technology And Research Method for diagnosis and prognosis of chronic heart failure
TWI696703B (zh) * 2015-09-30 2020-06-21 中央研究院 用以診斷心肌梗塞的方法及套組
CN105497057B (zh) * 2015-10-15 2019-01-15 中山大学 小分子非编码RNA miR-100在制备用于治疗肿瘤包绕型血管类型肝癌的药物中的应用
WO2017076974A1 (en) * 2015-11-05 2017-05-11 Academisch Medisch Centrum Biomarker for risk stratification in cardiovascular disease
US11459612B2 (en) 2015-12-01 2022-10-04 Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) Method for diagnosing cardiomyopathies
US10975436B2 (en) 2016-01-05 2021-04-13 Diamir, Llc Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders
WO2017165458A1 (en) 2016-03-21 2017-09-28 Diamir, Llc Methods of using mirnas from bodily fluids for detection and differentiation of neurodegenerative diseases
CN106119374A (zh) * 2016-07-05 2016-11-16 徐州医学院附属医院 一种microRNA‑133a的快速检测方法
CN109715218A (zh) * 2016-07-18 2019-05-03 嘉安生物治疗有限责任公司 用于治疗心脏疾病的组合物和方法
US11246883B2 (en) * 2016-09-30 2022-02-15 Academia Sinica Microrna let-7 and transforming growth factor beta receptor III axis as target for cardiac injuries
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
CN107050454B (zh) * 2016-12-09 2019-12-03 南方医科大学 一种miRNA-483-5p抑制剂药物及其在治疗骨关节炎药物中的用途
US10781487B2 (en) 2017-07-24 2020-09-22 Diamir, Llc miRNA-based methods for detecting and monitoring aging
US11225660B2 (en) 2017-10-12 2022-01-18 Emory University Methods and compositions for managing vascular conditions using miR-483 mimics and HIF1alpha pathway inhibitors
CN107858419A (zh) * 2017-11-10 2018-03-30 青岛大学 miRNA的应用、应用其的产品及检测方法
WO2021081006A1 (en) * 2019-10-21 2021-04-29 Jaan Biotherapeutics Llc Compositions and methods for mitigation of ischemic reperfusion injury
WO2021262919A2 (en) 2020-06-26 2021-12-30 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
CN112175951A (zh) * 2020-09-30 2021-01-05 深圳大学 一种miRNA-23a-5p抑制剂及其在制备治疗高盐损害疾病的药物中的应用
CN115181797B (zh) * 2022-04-19 2023-08-18 唐颢 MicroRNA在扩张型心肌病治疗中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002242116B2 (en) * 2001-02-07 2006-09-21 The General Hospital Corporation Methods for diagnosing and treating heart disease
JP2005502367A (ja) * 2001-09-11 2005-01-27 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド， ア ボディー コーポレイト インタクトなヒト心臓における発現プロファイリング
WO2005111211A2 (en) * 2004-05-14 2005-11-24 Rosetta Genomics Ltd. Micronas and uses thereof
EP2290076B1 (en) * 2004-05-28 2015-03-25 Asuragen, Inc. Methods and compositions involving microRNA
EP2631293A3 (en) * 2005-04-29 2013-11-20 The Rockefeller University Human microRNAs and methods for inhibiting same
US20090306181A1 (en) * 2006-09-29 2009-12-10 Children's Medical Center Corporation Compositions and methods for evaluating and treating heart failure
EP2094869B1 (de) * 2006-10-09 2012-07-25 Julius-Maximilians-Universität Würzburg Microrna (mirna) zur diagnose und therapie von herzerkrankungen

Also Published As

Publication number Publication date
CN101802227B (zh) 2014-12-10
AU2008275877A1 (en) 2009-01-22
WO2009012468A3 (en) 2009-04-16
KR20100049079A (ko) 2010-05-11
HK1143612A1 (en) 2011-01-07
US20150141495A1 (en) 2015-05-21
WO2009012468A2 (en) 2009-01-22
AU2008275877B2 (en) 2015-01-22
EP2179060A2 (en) 2010-04-28
CN101802227A (zh) 2010-08-11
US20100267804A1 (en) 2010-10-21
EP2179060A4 (en) 2010-12-29
EP2179060B1 (en) 2013-11-27
CA2693031A1 (en) 2009-01-22
JP2010533503A (ja) 2010-10-28

Similar Documents

Publication Publication Date Title
BRPI0813527A2 (pt) Expressão diferencial de micro-rnas em corações humanos que não falham versus que falham
EP2456310A4 (en) SUBSTITUTED BENZOIMIDAZOLSULFONAMIDES AND SUBSTITUTED INDOLSULFONAMIDES AS MGLUR4 POTENTIATORS
BRPI0807908A2 (pt) Melhoramentos em composições medicinais.
DK2138716T4 (da) Vingeindsats
BRPI0813710A2 (pt) Enzimas que produzem acetil-coa em levedura
IL211309A (en) Binder of energized components in an ophthalmic lens
EP2296593A4 (en) MEDICAL HEAD COVER
BR112012000391A2 (pt) expressão de representação visual baseada na expressão do jogador
BRPI0916763A2 (pt) dialisador
EP2365962A4 (en) AMINO ALCOHOL LIPIDOIDS AND APPLICATIONS THEREOF
PL3095452T3 (pl) Stosowanie kannabidiolu w połączeniu z arypiprazolem
BRPI0914789A2 (pt) efeitos sinérgicos
EP2257874A4 (en) DESIGN SIMULATION ON THE BASIS OF PARALLEL PROCESSORS
DK2349143T3 (da) Indføringsinstrument
BRPI0912803A2 (pt) couro natural
BRPI0910116A2 (pt) desvio transparente e mecanismos associados
EP2268297A4 (en) MODIFIED TOXINS
BRPI1014576A2 (pt) Emulsões nutricionais ricas em fibra
PT2309878T (pt) Purgantes dietéticos
DK2379722T3 (da) Ekspressionsvektor
DE112009002222A5 (de) Holzimitat
EP2170394A4 (en) T REGULATORY LYMPHOCYTES IN ADIPOSE TISSUE
EP2309854A4 (en) ACCELERATED THERAPY:
FI20085531A0 (fi) Ilmankäsittelylaite
IT1391542B1 (it) Cassaforte

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.